Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter

David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo

Mol Cancer Ther (2022) 21 (1): 237.

https://doi.org/10.1158/1535-7163.MCT-21-0212

Published: 07 January 2022

View article titled, Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter

Journal Articles

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Jennifer Donnell, Jing Xia, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg

Mol Cancer Ther (2018) 17 (1): 196–203.

https://doi.org/10.1158/1535-7163.MCT-17-0442

Published: 01 January 2018

View article titled, Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

Includes: Supplementary data

Journal Articles

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Thomas M. Cardillo, Serengulam V. Govindan, Maria B. Zalath, Diane L. Rossi, Yang Wang, Chien-Hsing Chang, David M. Goldenberg

Mol Cancer Ther (2018) 17 (1): 150–160.

https://doi.org/10.1158/1535-7163.MCT-17-0354

Published: 01 January 2018

View article titled, IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Includes: Supplementary data

Journal Articles

Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Chien-Hsing Chang, Yang Wang, Maria Zalath, Donglin Liu, Thomas M. Cardillo, David M. Goldenberg

Mol Cancer Ther (2016) 15 (8): 1910–1919.

https://doi.org/10.1158/1535-7163.MCT-16-0219

Published: 03 August 2016

View article titled, Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Includes: Supplementary data

Journal Articles

Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Thomas M. Cardillo, Serengulam V. Govindan, Maria Zalath, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg

Mol Cancer Ther (2015) 14 (12_Supplement_2): C166.

https://doi.org/10.1158/1535-7163.TARG-15-C166

Published: 01 December 2015

View article titled, Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Journal Articles

Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, David M. Goldenberg

Mol Cancer Ther (2014) 13 (10): 2341–2351.

https://doi.org/10.1158/1535-7163.MCT-14-0345

Published: 02 October 2014

View article titled, Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α

Includes: Supplementary data

Journal Articles

Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

Alexander N. Starodub, Allyson J. Ocean, Michael J. Guarino, Ellen Chuang, Manish A. Shah, Scott Tagawa, Vincent J. Picozzi, Sajeve S. Thomas, Pius P. Maliakal, William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg

Mol Cancer Ther (2013) 12 (11_Supplement): C67.

https://doi.org/10.1158/1535-7163.TARG-13-C67

Published: 01 November 2013

View article titled, Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

Journal Articles

Milatuzumab–SN-38 Conjugates for the Treatment of CD74⁺ Cancers

Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold, David M. Goldenberg

Mol Cancer Ther (2013) 12 (6): 968–978.

https://doi.org/10.1158/1535-7163.MCT-12-1170

Published: 09 June 2013

View article titled, Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Includes: Supplementary data

Journal Articles

Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg

Mol Cancer Ther (2012) 11 (1): 224–234.

https://doi.org/10.1158/1535-7163.MCT-11-0632

Published: 09 January 2012

View article titled, Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Includes: Supplementary data

Journal Articles

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan, David M. Goldenberg

Mol Cancer Ther (2011) 10 (6): 1072–1081.

https://doi.org/10.1158/1535-7163.MCT-11-0115

Published: 08 June 2011

View article titled, Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

Includes: Supplementary data

Journal Articles

Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

Chien-Hsing Chang, Pankaj Gupta, Rosana Michel, Meiyu Loo, Yang Wang, Thomas M. Cardillo, David M. Goldenberg

Mol Cancer Ther (2010) 9 (8): 2276–2286.

https://doi.org/10.1158/1535-7163.MCT-10-0338

Published: 09 August 2010

View article titled, Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

Includes: Supplementary data

Journal Articles

Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a ⁶⁸Ga- and ¹⁸F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts

Rafke Schoffelen, Robert M. Sharkey, David M. Goldenberg, Gerben Franssen, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, Peter Laverman, Jonathan A. Disselhorst, Annemarie Eek, Winette T.A. van der Graaf, Wim J.G. Oyen, Otto C. Boerman

Mol Cancer Ther (2010) 9 (4): 1019–1027.

https://doi.org/10.1158/1535-7163.MCT-09-0862

Published: 07 April 2010

View article titled, Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts

Journal Articles

Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts

Alice P. Taylor, David M. Goldenberg

Mol Cancer Ther (2007) 6 (2): 524–531.

https://doi.org/10.1158/1535-7163.MCT-06-0461

Published: 16 February 2007

View article titled, Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts

Includes: Supplementary data

Journal Articles

Sphingolipid targets in cancer therapy

David E. Modrak, David V. Gold, David M. Goldenberg

Mol Cancer Ther (2006) 5 (2): 200–208.

https://doi.org/10.1158/1535-7163.MCT-05-0420

Published: 27 February 2006

View article titled, Sphingolipid targets in cancer therapy

Journal Articles

A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy

Rhona Stein, David M. Goldenberg

Mol Cancer Ther (2004) 3 (12): 1559–1564.

https://doi.org/10.1158/1535-7163.1559.3.12

Published: 04 January 2005

View article titled, A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy

Journal Articles

Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies

Chien-Hsing Chang, Robert M. Sharkey, Edmund A. Rossi, Habibe Karacay, William McBride, Hans J. Hansen, Jean-François Chatal, Jacques Barbet, David M. Goldenberg

Mol Cancer Ther (2002) 1 (7): 553–563.

Published: 01 May 2002

View article titled, Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies

NARROW

Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α

Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

Milatuzumab–SN-38 Conjugates for the Treatment of CD74⁺ Cancers

Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

Pretargeted Immuno–Positron Emission Tomography Imaging of Carcinoembryonic Antigen–Expressing Tumors with a Bispecific Antibody and a ⁶⁸Ga- and ¹⁸F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts

Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts

Sphingolipid targets in cancer therapy

A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy

Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only